In March 2015, they have begun a phase I clinical trial of CPI-1205, a novel inhibitor of EZH2, in patients with B cell lymphomas (ClinicalTrials.gov identifier: NCT02395601). This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.